Share Price, page-3819

Whilst I agree we may not get to some of the heights discussed here, even though I also see the potential given the pipeline and revenue.

I think the biggest deal breaker is potentially come March 12th if the FDA goes in our favour we are 100% risk free (or as close to it as we can get), we have now a global commercial asset.

What valuation should a company with an asset generating potential revenue of pre tax AUD $50m-$200m+ p.a be worth of its Trof asset alone.

This is game changing, for comparisons one should be looking at companies with in BIO space, that generate similar revenues, as comparable as possible.

Others have already done this here.

NZ-2591 is x 5 of the above, so close to $1bn AUD in revenue annually.

$20 p/sh is cheap on any metrics.